Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by  Zacks Research  from a “purchase” ranking to a “hold” ranking in a research note provided to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on discovering and creating small molecule medication candidates to treat cancer cells. The Company‘s products under various phases of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research analysts also lately commented on the business. Noble Financial reissued a “purchase” score as well as issued a $11.00 cost objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and established a “acquire” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving average price of $2.90 as well as a two-hundred day moving ordinary rate of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an adverse net margin of 8,294.27%. The firm had income of $0.06 million throughout the quarter, compared to the consensus quote of $0.06 million. Throughout the very same quarter in the prior year, the company uploaded ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will post -1.18 EPS for the present year.

A number of hedge funds have actually recently bought and sold shares of ONTX. GSA Resources Partners LLP got a new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Management LP got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a brand-new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional financiers have 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the identification and also development of oncology therapeutics. It focuses on finding and also establishing small particle drug candidates to treat cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more details regarding research offerings from Zacks Investment Research, visit Zacks.com.

This immediate information alert was produced by narrative science innovation and economic information from Market in order to provide viewers with the fastest as well as most exact reporting. This tale was reviewed by Market’s content group before magazine. 



Before you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market monitors Wall Street’s top-rated and finest performing research experts as well as the stocks they advise to their customers on a daily basis. Market has determined the five stocks that top experts are quietly murmuring to their customers to acquire currently prior to the wider market catches on … and Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics currently has a “Buy” score among analysts, premier analysts think these five stocks are better gets.